Your session is about to expire
← Back to Search
NGAL Monitoring for Pediatric Acute Kidney Injury (Taking Focus 2 Trial)
N/A
Waitlist Available
Led By Stuart L Goldstein, MD
Research Sponsored by Children's Hospital Medical Center, Cincinnati
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48 hours
Awards & highlights
Taking Focus 2 Trial Summary
This trial will help doctors better predict and treat children at risk for developing severe acute kidney injury.
Who is the study for?
This trial is for children and newborns in the PICU, CICU, or NICU at participating hospitals who are at risk of developing severe acute kidney injury due to conditions like sepsis. It's not for those with advanced chronic kidney disease, recent kidney transplants, ongoing AKI needing dialysis before ICU admission, or if they're not expected to need intensive care for more than 48 hours.Check my eligibility
What is being tested?
The study tests a method using the Renal Angina Index (RAI) combined with biomarker testing and functional assessments to predict which patients will develop fluid overload and severe acute kidney injury after being admitted for sepsis or surgery.See study design
What are the potential side effects?
Since this trial involves diagnostic procedures rather than medications, traditional side effects are minimal. However, there may be some discomfort or risks associated with collecting blood samples or other necessary tests used in assessing renal function.
Taking Focus 2 Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 48 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48 hours
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Clinical Decision Support Performance
Secondary outcome measures
Rate of Clinical Decision Support Completion
Taking Focus 2 Trial Design
3Treatment groups
Experimental Treatment
Group I: PICU PatientsExperimental Treatment1 Intervention
Prospectively enrolled patients admitted to the PICU will be assessed by the RAI calibration for sepsis in the PICU and including additional risk factors.
Group II: NICU PatientsExperimental Treatment1 Intervention
Prospectively enrolled patients admitted to the NICU will be assessed by the RAI calibration for neonatal patients with sepsis or post abdominal surgeries
Group III: CICU PatientsExperimental Treatment1 Intervention
Prospectively enrolled patients admitted to the CICU will be assessed by the RAI calibration specific to the CICU, especially post cardiac bypass
Find a Location
Who is running the clinical trial?
Children's Hospital Medical Center, CincinnatiLead Sponsor
815 Previous Clinical Trials
6,530,140 Total Patients Enrolled
17 Trials studying Acute Kidney Injury
9,983 Patients Enrolled for Acute Kidney Injury
Stuart L Goldstein, MDPrincipal InvestigatorChildren's Hospital Medical Center, Cincinnati
3 Previous Clinical Trials
142 Total Patients Enrolled
3 Trials studying Acute Kidney Injury
142 Patients Enrolled for Acute Kidney Injury
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I started kidney replacement therapy before being admitted to the ICU due to acute kidney issues.You are not expected to need intensive care for more than 48 hours.You have a "do not resuscitate" order in place, or the medical team is not willing to provide advanced medical care if needed.My kidney function is very low (stage IV or V CKD).I had a kidney transplant in the last 3 months.
Research Study Groups:
This trial has the following groups:- Group 1: NICU Patients
- Group 2: PICU Patients
- Group 3: CICU Patients
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is enrollment for this trial currently open?
"According to the data on clinicaltrials.gov, this specific medical study is not currently accepting patients. Originating on September 1st 2022 and last updated November 10th 2021, although there are no openings now, 975 other trials remain open for enrolment."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger